Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
Authors:
Open Access
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) and atherosclerosis are cardiometabolic twin disorders with shared underlying pathophysiological mechanisms such as insulin resistance and chronic inflammation. This review explores the salient role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in linking hepatic dysfunction to cardiovascular disease. Findings in mice with genetic modulation of Ceacam1 gene established a critical role for CEACAM1 protein in regulating insulin and lipid metabolism and endothelial integrity and modulating immune response. Loss of CEACAM1 in hepatocytes impairs insulin clearance, causing chronic hyperinsulinemia, a process that ultimately leads to insulin resistance and hepatic and extra-hepatic fat accumulation, which in turn causes inflammatory infiltration. This prompts a paradigm shift that positions impaired hepatic CEACAM1 function as a mechanistic underpinning of the link between insulin resistance, MASH, and atherosclerosis.Keywords
Funding Information
- NIH (R01-DK054254, R01DK124126, R01-MD012579, R01-DK129877)
This publication has 305 references indexed in Scilit:
- Epidemiology of Heart FailureEuropean Journal of Heart Failure, 2020
- Efficiently Screening Heart Failure in Patients with Type 2 DiabetesEuropean Journal of Heart Failure, 2014
- Dietary fructose in nonalcoholic fatty liver diseaseHepatology, 2013
- Dendritic Cells Limit Fibroinflammatory Injury in Nonalcoholic Steatohepatitis in MiceHepatology, 2013
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesHepatology, 2012
- Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitisHepatology, 2010
- Increased Fructose Consumption Is Associated With Fibrosis Severity in Patients With Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels # †Hepatology, 2009
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡Hepatology, 2006
- Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver diseaseHepatology, 2005